ClinicalTrials.gg
CompletedNCT02258542BORAUpdated Aug 21, 2019Results posted

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

A Phase 3 interventional study of Benralizumab and Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 431 sites in 24 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,133
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
3rd of 39
2,133 · median 128
Started
2014
with 1 other
Phase 3
20 of 39
1 open now
Registered
11th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 20 in phase 3, and was the 11th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.

Read the detailed description

After a minimum of 1200 patients have been enrolled in this study, subsequent patients (up to a maximum of 2200 total for the study), who complete a minimum of 16 weeks, and no more than 40 weeks, in this study, will be given the option to transition to an open-label safety extension study, Study D3250C00037 (MELTEMI).

Adolescent patients, patients from Japan and South Korea, and any patient who chooses not to enter Study D3250C00037 will remain in this study through IPD or EOT and FU.

At the time of the first interim analysis in Japanese patients, the study regimen for all patients will become unblinded to AstraZeneca for data analysis purposes. Study conduct and blinding at the site and patient level will remain unchanged.

03

Conditions studied

  • Asthma

Keywords

  • Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (and/or assent as applicable locally) for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent(s)/guardian(s)) and according to international guidelines and/or applicable European Union guidelines.
  2. Female and male patients who completed the double-blind treatment period in a predecessor study on benralizumab or matching placebo.
  3. Women of (WOCBP) must agree to use an effective form of throughout the study duration and for 16 weeks after last dose of Product (IP).
  4. For WOCBP only: Have a negative urine pregnancy test prior to administration of Investigational Product (IP) at Visit 1.
  5. All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.

Exclusion criteria

Exclusion criteria

  1. Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  2. A helminth parasitic infection diagnosed during a predecessor study that has either not been treated, has been incompletely treated or has failed to respond to standard of care therapy
  3. Any change in physical examination, vital signs, (ECG), haematology, clinical chemistry, or urinalysis during a predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient's ability to complete the entire duration of the study
  4. Current or malignancy that developed during a predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded).
  5. Receipt of within 30 days prior to initiation of treatment in this study, during the treatment period, and for 16 weeks (5 half-lives) after the last dose of the product
  6. Receipt of immunoglobulin or blood products within 30 days prior to Visit 1
  7. Planned major surgical procedures during the conduct of the study
  8. Previous participation in the present study
  9. Concurrent enrolment in another clinical trial
  10. AstraZeneca staff involved in the planning and/or conduct of the study
  11. Employees of the study centre or any other individuals involved with the conduct of the study or immediate family members of such individuals
  12. Patients with major protocol deviations in any of the predecessor studies at the discretion of the Sponsor
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,133 participants (actual)

Study arms

  • Experimental
    Benralizumab Arm A

    Benralizumab administered subcutaneously

    Biological: Benralizumab

  • Experimental
    Benralizumab Arm B

    Benralizumab administered subcutaneously

    Biological: Benralizumab

Interventions

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in hematologic lab parameter of Basophils.

    Time frame: Week 56

  2. Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of Basophils.

    Time frame: Week 108

  3. Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in hematologic lab parameter of Leukocytes.

    Time frame: Week 56

  4. Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of Leukocytes.

    Time frame: Week 108

  5. Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in hematologic lab parameter of Lymphocytes.

    Time frame: Week 56

  6. Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of Lymphocytes.

    Time frame: Week 108

  7. Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in hematologic lab parameter of Neutrophils.

    Time frame: Week 56

  8. Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of Neutrophils.

    Time frame: Week 108

  9. Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in hematologic lab parameter of Eosinophils.

    Time frame: Week 56

  10. Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of Eosinophils.

    Time frame: Week 108

  11. Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in chemistry tests ALT.

    Time frame: Week 56

  12. Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of ALT.

    Time frame: Week 108

  13. Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in chemistry tests AST.

    Time frame: Week 56

  14. Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of AST.

    Time frame: Week 108

  15. Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients

    Change from baseline in chemistry test Bilirubin.

    Time frame: Week 56

  16. Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

    Change from baseline in hematologic lab parameter of Bilirubin.

    Time frame: Week 108

Secondary outcomes

  1. Number of Overall Patients With Asthma Exacerbations During Study Period

    Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

    Time frame: From week 0 to week 56 in study treatment period and through the follow up period (16 weeks from day of last dose)

  2. Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA)

    Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

    Time frame: From week 0 to week 108 in study treatment period and through the follow up period (16 weeks from day of last dose)

  3. Change From Baseline in Pre-bronchodilator FEV1 (L)

    Change from baseline to Week 56 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).

    Time frame: Week 56

  4. Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)

    Change from baseline to Week 108 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).

    Time frame: Week 108

  5. Change From Baseline in Post-bronchodilator FEV1 (L)

    Change from baseline to Week 56 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).

    Time frame: Week 56

  6. Change From Baseline in Post-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)

    Change from baseline to Week 108 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).

    Time frame: Week 108

  7. Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients

    Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.

    Time frame: Week 56

  8. Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients, Adolescents Only (SIROCCO/CALIMA)

    Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.

    Time frame: Week 108

  9. Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12)

    Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.

    Time frame: Week 56

  10. Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12), Adolescents Only (SIROCCO/CALIMA)

    Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.

    Time frame: Week 108

  11. Change of Blood Eosinophil Levels' Measurement in Overall Patients

    Change from baseline to Week 56 in Blood eosinophils

    Time frame: Week 56

  12. Change of Blood Eosinophil Levels' Measurement in Adolescents Patients (SIROCCO/CALIMA).

    Change from baseline to Week 108 in Blood eosinophils.

    Time frame: Week 108

  13. Change From Baseline in EQ-5D-5L Visual Analog Scale

    The questionnaire included a visual analog scale (VAS) score, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.

    Time frame: Week 56

  14. Change From Baseline in EQ-5D-5L Visual Analog Scale, Adolescents Only (SIROCCO/CALIMA)

    The questionnaire included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.

    Time frame: Week 108

  15. Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI)

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.

    Time frame: Week 68

  16. Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.

    Time frame: Week 108

  17. Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ)

    The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.

    Time frame: Week 56

  18. Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ), Adolescents Only (SIROCCO/CALIMA)

    The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.

    Time frame: Week 108

  19. Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI)

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: Week 68

  20. Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)

    The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: Week 108

  21. Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period

    Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma

    Time frame: From week 0 to week 68 in study treatment period and through the follow up period (16 weeks from day of last dose)

  22. Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period, Adolescents Only (SIROCCO/CALIMA)

    Hospitalizations, ED visits, urgent care visits and all other outpatient visits due to asthma

    Time frame: Baseline and Week 108

  23. Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study

    Endpoint: Pharmacokinetic (PK) parameters

    Time frame: Week 0 and Week 56

  24. Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study, Adolescents Only (SIROCCO/CALIMA)

    Endpoint: Pharmacokinetic (PK) parameters

    Time frame: Baseline and Week 108

  25. Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study

    Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study

    Time frame: From week 0 to week 56 in study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period

  26. Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study, Adolescents Only (SIROCCO/CALIMA)

    Assessments for the presence of ADA and nAb throughout study

    Time frame: From week 0 to week 108 study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period

07

Results

Posted Feb 6, 2019
Limitations and caveats
Patients in this study had to complete treatment in predecessor studies. Therefore selection bias may exist. Baseline is defined for this study's entry value, not all values are prior to active treatment due to some patients being treated previously.

Participant flow

2133 patients entered BORA. 10 were excluded due to a GCP breach. Of remaining 2123 patients, 1926 entered from SIROCCO/CALIMA and 197 from ZONDA. 2 patients were not treated, and a total of 447 patients (348 SIROCCO/CALIMA and 99 ZONDA) were later enrolled into MELTEMI without completing the follow-up in BORA, so not in the main analyses.

Participant flow — Overall Study
MilestoneSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Started95397310097
Treated95397110097
Adolescents only256100
Completed9119249292
Not completed424985
Withdrew: Eg. not made to the visit7401
Withdrew: Study specific discount. criteria1100
Withdrew: Withdrawal by subject202071
Withdrew: Lost to follow-up51212
Withdrew: Death5401
Withdrew: Adverse event3400
Withdrew: Protocol violation1200
Withdrew: Eligibility criteria not fulfilled0200

Outcome measures

PrimaryChange From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in hematologic lab parameter of Basophils.

Time frame:
Week 56
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients-0.005 ± 0.0223-0.005 ± 0.0239-0.007 ± 0.0283-0.005 ± 0.0244
PrimaryChange From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of Basophils.

Time frame:
Week 108
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)-0.006 ± 0.01450.001 ± 0.0208
PrimaryChange From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in hematologic lab parameter of Leukocytes.

Time frame:
Week 56
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients-0.344 ± 2.0412-0.128 ± 1.8614-0.808 ± 1.8177-0.507 ± 3.3612
PrimaryChange From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of Leukocytes.

Time frame:
Week 108
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)-0.487 ± 1.7289-0.079 ± 1.8432
PrimaryChange From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in hematologic lab parameter of Lymphocytes.

Time frame:
Week 56
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients-0.032 ± 0.62420.003 ± 0.5402-0.093 ± 0.64030.007 ± 0.6864
PrimaryChange From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of Lymphocytes.

Time frame:
Week 108
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)-0.180 ± 0.6946-0.070 ± 0.6671
PrimaryChange From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in hematologic lab parameter of Neutrophils.

Time frame:
Week 56
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients-0.171 ± 1.87460.013 ± 1.7024-0.501 ± 1.7096-0.368 ± 3.2057
PrimaryChange From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of Neutrophils.

Time frame:
Week 108
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)-0.451 ± 1.76450.242 ± 1.8469
PrimaryChange From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in hematologic lab parameter of Eosinophils.

Time frame:
Week 56
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients-0.1220 ± 0.30599-0.1271 ± 0.26161-0.1451 ± 0.30766-0.1664 ± 0.35139
PrimaryChange From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of Eosinophils.

Time frame:
Week 108
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
10^9 cells/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)-0.1294 ± 0.27973-0.1838 ± 0.3381
PrimaryChange From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in chemistry tests ALT.

Time frame:
Week 56
Reported as:
Mean · ukat/L
Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients
ukat/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients-0.007 ± 0.21020.017 ± 0.4651-0.064 ± 0.3547-0.023 ± 0.1940
PrimaryChange From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of ALT.

Time frame:
Week 108
Reported as:
Mean · ukat/L
Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
ukat/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)0.048 ± 0.21950.034 ± 0.2312
PrimaryChange From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in chemistry tests AST.

Time frame:
Week 56
Reported as:
Mean · ukat/L
Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients
ukat/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients-0.005 ± 0.14310.004 ± 0.3303-0.027 ± 0.2291-0.026 ± 0.1178
PrimaryChange From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of AST.

Time frame:
Week 108
Reported as:
Mean · ukat/L
Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
ukat/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)-0.006 ± 0.1196-0.013 ± 0.1297
PrimaryChange From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients

Change from baseline in chemistry test Bilirubin.

Time frame:
Week 56
Reported as:
Mean · umol/L
Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients
umol/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients0.187 ± 3.62610.391 ± 3.99450.146 ± 2.80940.279 ± 3.8765
PrimaryChange From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)

Change from baseline in hematologic lab parameter of Bilirubin.

Time frame:
Week 108
Reported as:
Mean · umol/L
Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)
umol/LSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)2.221 ± 8.34530.202 ± 3.6575
SecondaryNumber of Overall Patients With Asthma Exacerbations During Study Period

Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

Time frame:
From week 0 to week 56 in study treatment period and through the follow up period (16 weeks from day of last dose)
Reported as:
Count of participants · Participants
Number of Overall Patients With Asthma Exacerbations During Study Period
ParticipantsSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4ZONDA - Benralizumab 30 mg q.4 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8ZONDA - Benralizumab 30 mg q.8 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL — Number of exacerbation996015910466170——————
Sirocco/Calima patients with eos<300/μL — Number of exacerbation6944113653297——————
Zonda Patients with asthma exacerbations — Number of exacerbation——————12517131124
SecondaryNumber of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA)

Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit

Time frame:
From week 0 to week 108 in study treatment period and through the follow up period (16 weeks from day of last dose)
Reported as:
Count of participants · Participants
Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA)
ParticipantsSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL — Number of exacerbation268358
Sirocco/Calima patients with eos<300/μL — Number of exacerbation0005611
SecondaryChange From Baseline in Pre-bronchodilator FEV1 (L)

Change from baseline to Week 56 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).

Time frame:
Week 56
Reported as:
Mean · L
Change From Baseline in Pre-bronchodilator FEV1 (L)
LSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4ZONDA - Benralizumab 30 mg q.4 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8ZONDA - Benralizumab 30 mg q.8 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-0.006 ± 0.2950.131 ± 0.4220.038 ± 0.3460.019 ± 0.3170.081 ± 0.4190.040 ± 0.356——————
Sirocco/Calima patients with eos<300/μL-0.021 ± 0.376-0.011 ± 0.280-0.017 ± 0.345-0.015 ± 0.2930.030 ± 0.350-0.001 ± 0.312——————
Number of Zonda Patients——————0.013 ± 0.3540.167 ± 0.5330.057 ± 0.412-0.093 ± 0.2800.138 ± 0.329-0.012 ± 0.314
SecondaryChange From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)

Change from baseline to Week 108 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1).

Time frame:
Week 108
Reported as:
Mean · L
Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)
LSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL0.205 ± 0.289-0.189 ± 0.354-0.020 ± 0.3750.578 ± 0.6080.413 ± 0.3750.496 ± 0.502
Sirocco/Calima patients with eos<300/μL0.325 ± 0.4311.140 ± NA0.597 ± 0.5610.047 ± 0.3400.240 ± 0.5190.147 ± 0.444
SecondaryChange From Baseline in Post-bronchodilator FEV1 (L)

Change from baseline to Week 56 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).

Time frame:
Week 56
Reported as:
Mean · L
Change From Baseline in Post-bronchodilator FEV1 (L)
LSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-0.066 ± 0.2800.089 ± 0.455-0.015 ± 0.354-0.029 ± 0.2810.045 ± 0.401-0.004 ± 0.329
Sirocco/Calima patients with eos<300/μL-0.058 ± 0.379-0.024 ± 0.289-0.046 ± 0.350-0.043 ± 0.2730.049 ± 0.394-0.015 ± 0.316
SecondaryChange From Baseline in Post-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)

Change from baseline to Week 108 in Post-bronchodilator Forced expiratory volume in 1 second (FEV1).

Time frame:
Week 108
Reported as:
Mean · L
Change From Baseline in Post-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)
LSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-0.062 ± 0.537-0.305 ± 0.394-0.201 ± 0.4580.603 ± 0.7490.279 ± 0.6590.448 ± 0.712
Sirocco/Calima patients with eos<300/μL0.375 ± 0.4740.880 ± NA0.543 ± 0.444-0.006 ± 0.3270.218 ± 0.5360.111 ± 0.454
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients

Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.

Time frame:
Week 56
Reported as:
Mean · Score on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients
Score on a scaleSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4ZONDA - Benralizumab 30 mg q.4 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8ZONDA - Benralizumab 30 mg q.8 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-0.04 ± 0.83-0.20 ± 1.04-0.09 ± 0.91-0.06 ± 0.82-0.25 ± 1.06-0.12 ± 0.91——————
Sirocco/Calima patients with eos<300/μL-0.16 ± 0.90-0.12 ± 0.80-0.15 ± 0.86-0.10 ± 0.83-0.09 ± 1.06-0.10 ± 0.90——————
Number of Zonda Patients——————-0.05 ± 0.89-0.61 ± 0.74-0.21 ± 0.870.15 ± 1.02-0.43 ± 1.00-0.05 ± 1.04
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients, Adolescents Only (SIROCCO/CALIMA)

Asthma Control Questionnaire 6 (ACQ-6) contains 1 bronchodilator use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses.

Time frame:
Week 108
Reported as:
Mean · Score on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients, Adolescents Only (SIROCCO/CALIMA)
Score on a scaleSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL0.26 ± 0.530.06 ± 0.490.16 ± 0.50-0.14 ± 0.51-0.10 ± 1.38-0.12 ± 1.02
Sirocco/Calima patients with eos<300/μL-0.50 ± 0.24-1.83 ± NA0.94 ± 0.79-0.21 ± 0.78-0.21 ± 0.77-0.21 ± 0.76
SecondaryChange From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12)

Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.

Time frame:
Week 56
Reported as:
Mean · Score on a scale
Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12)
Score on a scaleSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4ZONDA - Benralizumab 30 mg q.4 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8ZONDA - Benralizumab 30 mg q.8 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL0.02 ± 0.800.21 ± 0.980.08 ± 0.870.08 ± 0.910.26 ± 1.000.15 ± 0.94——————
Sirocco/Calima patients with eos<300/μL0.11 ± 0.840.03 ± 0.890.09 ± 0.850.15 ± 0.900.02 ± 1.060.11 ± 0.95——————
Number of Zonda Patients——————0.13 ± 0.930.43 ± 0.910.22 ± 0.92-0.04 ± 0.940.40 ± 1.030.11 ± 0.98
SecondaryChange From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12), Adolescents Only (SIROCCO/CALIMA)

Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli). It contains 32 questions on a 7 point scale ranging from 7 (no impairment) to 1 (severe impairment); total score is an average of all questions. An increase in score indicates improvement.

Time frame:
Week 108
Reported as:
Mean · Score on a scale
Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12), Adolescents Only (SIROCCO/CALIMA)
Score on a scaleSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL0.60 ± 1.22-0.11 ± 0.210.25 ± 0.920.52 ± 0.370.06 ± 0.590.29 ± 0.54
Sirocco/Calima patients with eos<300/μL0.64 ± 0.551.53 ± NA0.94 ± 0.650.58 ± 1.010.27 ± 0.770.42 ± 0.89
SecondaryChange of Blood Eosinophil Levels' Measurement in Overall Patients

Change from baseline to Week 56 in Blood eosinophils

Time frame:
Week 56
Reported as:
Mean · cell/uL
Change of Blood Eosinophil Levels' Measurement in Overall Patients
cell/uLSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 - Pre Benra q.4ZONDA - Benralizumab 30 mg q.4 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 - Pre Benra q.8ZONDA - Benralizumab 30 mg q.8 - Predecessor PlaceboZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL4.9 ± 177.42-449.6 ± 360.6-148.6 ± 332.91-10.1 ± 134.7-422.5 ± 330.01-154.1 ± 297.34——————
Sirocco/Calima patients with eos<300/μL15.7 ± 87.04-222.1 ± 325.03-68.4 ± 234.40-2.9 ± 59.11-217.4 ± 198.56-74.7 ± 160.29——————
Number of Zonda Patients——————2.5 ± 69.85-520.9 ± 360.79-145.1 ± 307.66-17.0 ± 107.48-435.3 ± 468.64-166.4 ± 351.39
SecondaryChange of Blood Eosinophil Levels' Measurement in Adolescents Patients (SIROCCO/CALIMA).

Change from baseline to Week 108 in Blood eosinophils.

Time frame:
Week 108
Reported as:
Mean · cell/uL
Change of Blood Eosinophil Levels' Measurement in Adolescents Patients (SIROCCO/CALIMA).
cell/uLSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL78.3 ± 192.19-356.7 ± 215.47-139.2 ± 299.16-163.6 ± 502.76-332.9 ± 349.89-229.4 ± 446.21
Sirocco/Calima patients with eos<300/μL160.0 ± NA-150.0 ± NA5.0 ± 219.20-2.0 ± 9.19-204.4 ± 152.32-97.9 ± 145.40
SecondaryChange From Baseline in EQ-5D-5L Visual Analog Scale

The questionnaire included a visual analog scale (VAS) score, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.

Time frame:
Week 56
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D-5L Visual Analog Scale
Score on a scaleSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL6.08 ± 15.686.02 ± 17.68——
Sirocco/Calima patients with eos<300/μL4.38 ± 14.996.69 ± 15.96——
Number of Zonda Patients——5.00 ± 10.351.36 ± 13.58
SecondaryChange From Baseline in EQ-5D-5L Visual Analog Scale, Adolescents Only (SIROCCO/CALIMA)

The questionnaire included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state; thus, an increase in VAS score indicated improvement.

Time frame:
Week 108
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D-5L Visual Analog Scale, Adolescents Only (SIROCCO/CALIMA)
Score on a scaleSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL5.43 ± 9.736.63 ± 15.536.07 ± 12.7111.54 ± 26.959.83 ± 13.8710.72 ± 21.26
Sirocco/Calima patients with eos<300/μL22.00 ± 12.73-4.00 ± NA13.33 ± 17.5010.18 ± 32.695.08 ± 10.457.52 ± 23.39
SecondaryWork Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI)

The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.

Time frame:
Week 68
Reported as:
Mean · percentage
Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI)
percentageSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-wk 6823.3 ± 26.1821.0 ± 25.54——
Sirocco/Calima patients with eos<300/μL-wk 6832.7 ± 27.5525.8 ± 24.05——
Zonda Patients-wk 68——18.9 ± 24.9421.0 ± 27.13
SecondaryWork Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)

The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Work productivity loss is calculated with sum of hours missed at work due to health problem and hours that affected due to health problem at work, divided by sum of hours missed due to health problem and hours actually worked, presented by percentage.

Time frame:
Week 108
Reported as:
Mean · Percentage
Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)
PercentageSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-wk 1080.0 ± 0.0010.0 ± NA3 ± 3.320.0 ± NA10.0 ± NA15.0 ± 7.07
Sirocco/Calima patients with eos<300/μL-wk-108———0.0 ± 0.0013.3 ± 5.778.0 ± 8.37
SecondaryClassroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ)

The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.

Time frame:
Week 56
Reported as:
Mean · Percentage
Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ)
PercentageSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-wk 563.8 ± 7.4415.2 ± 20.69——
Sirocco/Calima patients with eos<300/μL-wk 565.0 ± 7.0717.1 ± 20.06——
SecondaryClassroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ), Adolescents Only (SIROCCO/CALIMA)

The WPAI (+CIQ) is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. Classroom productivity loss is calculated with sum of hours missed for classes due to health problem and hours that affected due to health problem in classes, divided by sum of hours missed due to health problem and hours actually attended classes, presented by percentage.

Time frame:
Week 108
Reported as:
Mean · Percentage
Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ), Adolescents Only (SIROCCO/CALIMA)
PercentageSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-wk 1084.9 ± 6.8215.2 ± 17.559.5 ± 12.985.4 ± 8.3218.6 ± 27.9412.3 ± 21.62
Sirocco/Calima patients with eos<300/μL-wk-10821.5 ± 30.41—21.5 ± 30.4112.5 ± 18.1010.6 ± 11.6811.5 ± 14.66
SecondaryActivity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI)

The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Time frame:
Week 68
Reported as:
Mean · percentage
Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI)
percentageSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-wk 6826.6 ± 26.1424.4 ± 25.26——
Sirocco/Calima patients with eos<300/μL-wk 6833.6 ± 26.5532.7 ± 26.58——
Zonda Patients-wk 68——28.4 ± 27.8539.0 ± 34.36
SecondaryActivity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)

The WPAI+CIQ is a 10-item questionnaire that assesses productivity and activity impairment over the previous week. The questionnaire includes hours missed from work/school due to asthma, degree health affected productivity while at work/school, as well as the degree to which health affected regular activities other than work or school. The questionnaire related to the previous 7 days. The WPAI+CIQ outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Time frame:
Week 108
Reported as:
Mean · Percentage
Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)
PercentageSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL-wk 1087.1 ± 11.135.0 ± 9.266.0 ± 9.865.4 ± 8.7719.2 ± 24.3112.3 ± 19.25
Sirocco/Calima patients with eos<300/μL-wk-10810.0 ± 14.1420.0 ± NA13.3 ± 11.5514.2 ± 18.8111.5 ± 10.6812.8 ± 14.87
SecondaryNumber of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period

Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma

Time frame:
From week 0 to week 68 in study treatment period and through the follow up period (16 weeks from day of last dose)
Reported as:
Count of participants · Participants
Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period
ParticipantsSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL193198——
Sirocco/Calima patients with eos<300/μL118102——
Number of Zonda Patients——2025
SecondaryNumber of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period, Adolescents Only (SIROCCO/CALIMA)

Hospitalizations, ED visits, urgent care visits and all other outpatient visits due to asthma

Time frame:
Baseline and Week 108
Reported as:
Count of participants · Participants
Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period, Adolescents Only (SIROCCO/CALIMA)
ParticipantsSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Sirocco/Calima patients with eos>=300/μL2577714
Sirocco/Calima patients with eos<300/μL0117512
SecondaryPre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study

Endpoint: Pharmacokinetic (PK) parameters

Time frame:
Week 0 and Week 56
Reported as:
Geometric mean · ng/mL
Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study
ng/mLSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor PlaceboZONDA - Benra 30 mg q.4 Weeks - Pre Benra q.4ZONDA - Benra 30 mg q.4 wk - Predecessor PlaceboZONDA - Benra 30 mg q.8 Weeks - Pre Benra q.8ZONDA - Benra 30 mg q.8 wk - Predecessor Placebo
Baseline714.25 (624.48 to 816.93)NA (NA to NA)142.92 (124.08 to 164.63)NA (NA to NA)964.21 (589.87 to 1576.11)NA (NA to NA)692.91 (428.49 to 1120.50)NA (NA to NA)
Week 56930.04 (825.89 to 1047.33)865.93 (721.50 to 1039.27)173.95 (151.81 to 199.33)162.03 (132.31 to 195.43)823.62 (476.98 to 1422.17)1160.58 (833.77 to 1615.49)247.26 (165.87 to 368.57)139.35 (61.90 to 313.70)
SecondaryPre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study, Adolescents Only (SIROCCO/CALIMA)

Endpoint: Pharmacokinetic (PK) parameters

Time frame:
Baseline and Week 108
Reported as:
Geometric mean · ng/mL
Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study, Adolescents Only (SIROCCO/CALIMA)
ng/mLSIROCCO/CALIMA - Benralizumab 30 mg q.4 - Pre Benra q.4SIROCCO/CALIMA - Benralizumab 30 mg q.4 - Predecessor PlaceboSIROCCO/CALIMA - Benralizumab 30 mg q.8 - Pre Benra q.8SIROCCO/CALIMA - Benralizumab 30 mg q.8 - Predecessor Placebo
Baseline725.55 (231.38 to 2275.13)NA (NA to NA)218.53 (126.53 to 377.42)NA (NA to NA)
Week 108383.73 (30.90 to 4764.79)853.51 (260.26 to 2799.03)436.85 (185.36 to 1029.59)524.39 (287.72 to 955.74)
SecondaryNumber of Patients With Anti-drug Antibodies (ADA) Responses During the Study

Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study

Time frame:
From week 0 to week 56 in study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period
Reported as:
Number · Participants
Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study
ParticipantsSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Positive at any visit809348
Base- and Post-baseline Positive234124
Newly Persistently Positive283413
Stable persistently positive212922
Newly treatment-induced positive384122
ADA treatment boosted positive6601
Decreased in titre17921
Only post-baseline positive484821
ADA incidence444723
Transiently Positive222613
Only baseline positive9400
nAb positive577534
SecondaryNumber of Patients With Anti-drug Antibodies (ADA) Responses During the Study, Adolescents Only (SIROCCO/CALIMA)

Assessments for the presence of ADA and nAb throughout study

Time frame:
From week 0 to week 108 study treatment period (adults) and plus 16 weeks the follow up period; From week 0 to week 108-week in study treatment period (adolescents) and plus 16 weeks the follow up period
Reported as:
Number · Participants
Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study, Adolescents Only (SIROCCO/CALIMA)
ParticipantsSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks
Positive at any visit15
Base- and Post-baseline Positive03
Newly Persistently Positive02
Stable persistently positive03
Newly treatment-induced positive11
ADA treatment boosted positive02
Decreased in titre02
Only post-baseline positive12
ADA incidence13
Transiently Positive10
Only baseline positive00
nAb positive15

Adverse events

Collected over Adults completed 56 weeks of treatment period and 12 weeks follow-up period; and adolescents completed 108 weeks of treatment period and 12 weeks follow-up period.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SIROCCO/CALIMA - Benralizumab 30 mg q.4 Weeks5/783 (0.6%)102/783 (13%)415/783 (53%)
SIROCCO/CALIMA - Benralizumab 30 mg q.8 Weeks4/793 (0.5%)94/793 (11.9%)409/793 (51.6%)
ZONDA - Benralizumab 30 mg q.4 Weeks0/49 (0%)10/49 (20.4%)33/49 (67.3%)
ZONDA - Benralizumab 30 mg q.8 Weeks1/49 (2%)9/49 (18.4%)38/49 (77.6%)
Most frequent serious events
Showing 10 of 142
Most frequent serious events
EventSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
AsthmaRespiratory, thoracic and mediastinal disorders36/78326/7933/492/49
Iron deficiency anaemiaBlood and lymphatic system disorders0/7830/7931/490/49
Acute myocardial infarctionCardiac disorders1/7832/7931/490/49
Inguinal herniaGastrointestinal disorders0/7831/7930/491/49
PneumoniaInfections and infestations2/7834/7930/491/49
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7830/7930/491/49
Colitis ulcerativeGastrointestinal disorders0/7830/7930/491/49
GastritisGastrointestinal disorders2/7830/7931/490/49
DiverticulitisInfections and infestations0/7830/7931/490/49
Lower respiratory tract infectionInfections and infestations0/7830/7930/491/49
Most frequent other events
Showing 10 of 36
Most frequent other events
EventSIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 Weeks
Viral upper respiratory tract infectionInfections and infestations124/783130/79314/4913/49
BronchitisInfections and infestations50/78351/7933/4910/49
Upper respiratory tract infectionInfections and infestations61/78356/7930/497/49
AsthmaRespiratory, thoracic and mediastinal disorders62/78353/7934/497/49
ArthralgiaMusculoskeletal and connective tissue disorders26/78320/7935/490/49
Oedema peripheralGeneral disorders4/7836/7930/494/49
SinusitisInfections and infestations22/78318/7933/494/49
Back painMusculoskeletal and connective tissue disorders24/78321/7932/494/49
HeadacheNervous system disorders38/78340/7932/494/49
Influenza like illnessGeneral disorders27/78330/7933/491/49

Baseline characteristics

Full analysis population defined as treated for at least 1 treatment, excluding patients enrolled in MELTEMI.

Age, Continuous
Age, Continuous(Years)SIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 WeeksTotal
Mean51.1 ± 13.7948.9 ± 15.5349.7 ± 10.3552.7 ± 8.9050.1 ± 14.48
Sex: Female, Male
Sex: Female, Male(Participants)SIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 WeeksTotal
Female50347027291029
Male2803232220645
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SIROCCO/CALIMA - Benralizumab 30 mg q.4 WeeksSIROCCO/CALIMA - Benralizumab 30 mg q.8 WeeksZONDA - Benralizumab 30 mg q.4 WeeksZONDA - Benralizumab 30 mg q.8 WeeksTotal
White59961245421298
Black and African American16190136
Asian13813646284
Other30260056
08

Study locations

431 sites
  • Research Site
    Andalusia, Alabama 36420, United States
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Scottsboro, Alabama 35768, United States
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Phoenix, Arizona 85012, United States
  • Research Site
    Alhambra, California 91801, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Stockton, California 95204, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Woodland, California 95695, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Cutler Bay, Florida 33189, United States
  • Research Site
    Doral, Florida 33172, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hialeah, Florida 33013, United States
  • Research Site
    Homestead, Florida 33030, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33134, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Ocala, Florida 34471-4463, United States
  • Research Site
    Orlando, Florida 32819, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Albany, Georgia 31707, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Gurnee, Illinois 60031, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Fort Mitchell, Kentucky 41017, United States
  • Research Site
    Louisville, Kentucky 40215, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Baltimore, Maryland 21236, United States
  • Research Site
    Quincy, Massachusetts 02169, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Traverse City, Michigan 49684, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Paul, Minnesota 55130, United States
  • Research Site
    Saint Louis, Missouri 63143, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    Union, New Jersey 07083, United States
  • Research Site
    Albuquerque, New Mexico 87131, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Staten Island, New York 10305, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Middleburg Heights, Ohio 44130, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Oklahoma City, Oklahoma 73131, United States
  • Research Site
    Tulsa, Oklahoma 74136, United States
  • Research Site
    Jefferson Hills, Pennsylvania 15025, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Pittsburgh, Pennsylvania 15241, United States
  • Research Site
    Warwick, Rhode Island 02886, United States
  • Research Site
    Hodges, South Carolina 29653, United States
  • Research Site
    Rapid City, South Dakota 57702, United States
  • Research Site
    Arlington, Texas 76018, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    Dallas, Texas 75225, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77058, United States
  • Research Site
    Houston, Texas 77081, United States
  • Research Site
    Houston, Texas 77083, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    McAllen, Texas 78504, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Splendora, Texas 77372, United States
  • Research Site
    Provo, Utah 84604, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Falls Church, Virginia 22044, United States
  • Research Site
    Greenfield, Wisconsin 53228, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States

Showing the first 100 of 431 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Brooks L, Olsson RF, Martin UJ, Goldman M; BORA study investigators. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. J Allergy Clin Immunol. 2021 Jul;148(1):266-271.e2. doi: 10.1016/j.jaci.2021.02.009. Epub 2021 Feb 17. PubMed 33609624 ↗
  • Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum In: Lancet Respir Med. 2019 Jan;7(1):e1. doi: 10.1016/S2213-2600(18)30518-6. PubMed 30416083 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Oct 2017, 34 months.

Results were first posted in Feb 2019, 1 year 3 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 34 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2014
First posted
Oct 7, 2014
StartActual
Nov 19, 2014
Primary completionActual
Oct 18, 2017
CompletionActual
Jul 2, 2018
Results first posted
Feb 6, 2019
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02258542
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 7, 2014
Start date
Nov 19, 2014
Primary completion
Oct 18, 2017
Completion
Jul 2, 2018
Results posted
Feb 6, 2019
Last update
Aug 21, 2019

Study contacts

William W. Busse, M.D., Professor of Medicine
principal investigator · Allergy, Pulmonary, and Critical Care Medicine 600 Highland Avenue; Madison, WI

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion